Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024	Dec. 31, 2023
Product Information [Line Items]
Operating revenues	$ 986,820	$ 760,985	$ 2,734,915	$ 2,090,047
Income from equity method investments	5,540	3,833	11,577	7,797
Net asset, equity method investment	18,400		18,400		$ 14,300
Cash, cash equivalents and restricted cash	149,167	553	149,167	553	86,012	$ 1,567
Restricted cash and cash equivalents	19,300		19,300		$ 16,100
Net investment income	1,300		2,800
Central Cash Management
Product Information [Line Items]
Net investment income	1,200		2,700
Captive Cell
Product Information [Line Items]
Net investment income	$ 100		$ 100
Related party | Allocated Corporate Expenses
Product Information [Line Items]
General corporate expenses		4,900		27,600
Corporate joint venture
Product Information [Line Items]
Operating revenues		100		600
Income from proportionate consolidation, joint ventures		0		$ 200
Income from equity method investments		$ 3,800